GlassScriptPhysician profile
John R Mcrae
NPI 1245334333
$2,844.87
in general payments reported to CMS, 2019-2025
29 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $271 · 2021: $526 · 2022: $48.44 · 2023: $734 · 2024: $711 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $507.23 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $249.96 | 2019-2024 | Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $245.52 | 2023-2025 | Gvoke Hypopen |
| Cequr Corporation | $198.03 | 2023-2025 | Cequr Simplicity |
| Dexcom, INC. | $192.65 | 2020-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.52 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $117.73 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $111.49 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $109.82 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $103.78 | 2023-2024 | Omnipod |
| Abbott Laboratories | $101.80 | 2020-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $98.90 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $92.96 | 2024-2025 | |
| Medtronic, INC. | $91.29 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbvie INC. | $86.74 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.77 | 2020-2021 | |
| Esperion Therapeutics, INC. | $49.90 | 2021 | |
| Ascendis Pharma Endocrinology INC | $46.03 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $35.73 | 2021 | |
| Ibsa Pharma INC. | $35.03 | 2024 | Tirosint, Licart |
| Lifescan, INC. | $30.26 | 2020-2021 | |
| Clarus Therapeutics INC. | $27.06 | 2021 | |
| Companion Medical, INC. | $26.73 | 2020 | |
| Merck Sharp & Dohme LLC | $21.25 | 2021 | |
| Recordati_rare_diseases_inc. | $19.27 | 2021 | |
| Amgen INC. | $17.72 | 2020 | |
| Radius Health, INC. | $14.01 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcrae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.